Strut Health BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Strut Health a Legitimate Telehealth Company?

Strut Health operates as a licensed telehealth platform and compounds medications through a partnered 503A-registered pharmacy. That means it is legal, but legality and quality are not the same thing. Patients evaluating any cash telehealth brand should check FDA registration, LegitScript certification, and state pharmacy board licensure rather than relying solely on marketing copy or star ratings.

What "Legitimate" Means in Telehealth

The word "legit" is often used loosely. In regulatory terms, a telehealth pharmacy meets minimum legitimacy if it employs state-licensed prescribers, dispenses through a state-licensed pharmacy, and follows FDA compounding rules under 21 U.S.C. §353a (503A) or §353b (503B). The FDA maintains a public database of registered outsourcing facilities at fda.gov, and patients can cross-reference any compound pharmacy's name there. [1]

Asynchronous Prescribing: Convenience vs. Oversight Risk

Strut Health uses an asynchronous model: patients submit a photo questionnaire, a licensed clinician reviews it offline, and a prescription is issued without a live encounter. The American Telemedicine Association notes that asynchronous models are clinically appropriate for certain dermatological and low-acuity conditions but recommends that platforms have clear escalation protocols for adverse events. [2] When complaints arise at Strut Health or similar platforms, they frequently trace back to gaps in that escalation path, meaning a patient experienced a side effect and could not reach a clinician quickly.

LegitScript Certification

LegitScript is an independent third-party monitor that certifies online pharmacies. Its certification standards require verification of prescriber licensure, pharmacy licensure, and drug sourcing. As of the date this article was reviewed, patients are advised to check legitscript.com directly for Strut Health's current status, because certification can lapse and databases update in real time. A lapsed or absent LegitScript certification is not automatic proof of fraud, but it removes one layer of independent oversight.

Strut Health BBB Profile: What the Complaints Actually Show

The Better Business Bureau is not a government regulator and has no enforcement authority. Its value is as a structured complaint log where patterns become visible over time. Strut Health holds a BBB profile with a limited complaint history relative to the scale of cash telehealth companies, but the complaint themes that do appear are consistent with industry-wide friction points.

Complaint Volume in Context

A small absolute complaint count does not automatically signal a trustworthy company. A brand serving 50,000 patients and logging 30 BBB complaints in 12 months has a complaint rate of 0.06%, which is lower than many brick-and-mortar pharmacy chains. Context matters. The BBB itself states that its ratings reflect "the BBB's opinion of how the business is likely to interact with its customers," factoring in complaint history, time in business, and whether complaints were resolved. [3] Strut Health's rating should be read alongside resolution rates, not just raw complaint counts.

Recurring Complaint Themes

Three themes dominate consumer complaints about Strut Health across BBB, Trustpilot, and Reddit discussions (the latter two are informal, not regulatory):

Billing and subscription charges. Patients report being charged for refills they did not authorize or difficulty canceling auto-ship subscriptions. This is the most common complaint category across cash telehealth brands generally, not just Strut Health.

Prescription delays and communication gaps. Compounded medications have longer lead times than commercially manufactured drugs. Patients who expected a 3-to-5-day turnaround and received their order in 14 days filed complaints about lack of proactive communication during the delay.

Compounded-drug labeling and dosing confusion. Compounded semaglutide and tirzepatide, in particular, have generated complaints about unclear dosing instructions. The FDA issued a safety communication in May 2024 warning that compounded semaglutide products lack the standardized labeling of FDA-approved Ozempic or Wegovy, and that dosing errors have been reported. [4]

How BBB Complaint Resolution Works

The BBB forwards complaints to the business and tracks whether the company responds and resolves the issue. A company can resolve a complaint while still receiving a negative review. Strut Health's public BBB file shows a response rate to complaints, and patients whose complaints were resolved typically received refunds or replacement shipments. That pattern suggests an operational customer-service function, not a vanishing-act scam, but it does not excuse the root-cause billing or communication failures that generated the complaints in the first place.

FDA and Compounding Pharmacy Oversight: The Regulatory Layer That Actually Matters

For a cash telehealth platform that sells compounded drugs, FDA oversight is more consequential than any consumer-review score. The FDA regulates compounding under two frameworks, and understanding which one applies to Strut Health's pharmacy partner changes how patients should evaluate risk.

503A vs. 503B: The Critical Distinction

A 503A pharmacy compounds medications for individual patients based on a valid prescription. It is exempt from FDA's new drug approval requirements and GMP (Good Manufacturing Practice) regulations, but it must use FDA-approved bulk drug substances. Compounds must be made in a licensed pharmacy and cannot be sold wholesale. [1]

A 503B outsourcing facility produces larger batches, is subject to FDA inspection and GMP standards, and can sell to healthcare providers without patient-specific prescriptions. The FDA publishes a list of registered 503B facilities at fda.gov.

Strut Health's pharmacy partner operates under 503A. That means each compound is patient-specific and prescription-triggered, but there is no mandatory FDA pre-inspection. State boards of pharmacy are the primary inspectors for 503A pharmacies. Patients should verify their state board has current licensure for the dispensing pharmacy, not just Strut Health's front-end platform.

Compounded Semaglutide and the FDA's 2024 Shortage Actions

From March 2022 through early 2025, semaglutide injection (Ozempic, Wegovy) appeared on the FDA drug-shortage list, which legally allowed 503A and 503B pharmacies to compound copies. The FDA removed semaglutide from the shortage list in February 2025, triggering a compliance deadline. After that deadline, 503A pharmacies may no longer compound copies of FDA-approved semaglutide products for most patients. [4]

Any Strut Health patient currently receiving compounded semaglutide should ask their prescriber whether the product still complies with post-shortage-resolution rules. A failure to do so is a regulatory violation by the pharmacy, not the patient, but the patient bears the practical consequence of a disrupted prescription.

FDA Warning Letters to Telehealth Compounders

The FDA has issued warning letters to multiple telehealth-adjacent compounding pharmacies for violations including lack of adequate beyond-use dating, failure to test for sterility in injectable compounds, and marketing unapproved drugs. [5] Strut Health itself had not received a public FDA warning letter as of the review date of this article, but patients should check fda.gov/inspections-compliance-enforcement directly, because warning letters are issued continuously.

Strut Health's Core Treatment Categories: Clinical Grounding

Evaluating complaints requires knowing whether the underlying treatments are evidence-based. Strut Health focuses on three categories: androgenic alopecia, erectile dysfunction, and peptides. The evidence profiles differ substantially across them.

Hair Loss: Finasteride and Minoxidil

Oral finasteride 1 mg daily is FDA-approved for male androgenic alopecia. In a 2-year randomized trial of 1,553 men, finasteride produced a 48% increase in hair count vs. A 14% decrease in the placebo group (P<0.001). [6] Topical minoxidil 5% solution is also FDA-approved; a 48-week trial showed 45% of men using minoxidil had moderate to dense hair regrowth vs. 7% for placebo. [7]

Strut Health offers compounded topical combinations (for example, finasteride plus minoxidil in a single topical vehicle). These combinations are not FDA-approved as a unit, but the individual active ingredients are FDA-approved. The American Academy of Dermatology guidelines support combination therapy for androgenic alopecia. [8] Patient complaints in this category tend to center on shipping delays, not drug efficacy disputes.

Erectile Dysfunction: Sildenafil and Tadalafil

Sildenafil (Viagra) and tadalafil (Cialis) are both FDA-approved PDE5 inhibitors with decades of safety data. The PDE5 inhibitor class showed consistent NNT (number needed to treat) of 3 to 5 for achieving erections sufficient for intercourse in clinical trials. [9] Strut Health offers compounded sildenafil and tadalafil in non-standard doses or formulations. Again, the active molecules are proven; the compounded vehicle and dosage form carry the regulatory caveat of lacking FDA approval as a finished product.

Complaints in this category occasionally involve patients receiving incorrect doses. Compounding errors are a documented risk: a 2022 USP analysis found that 9% of compounded drug samples tested outside of acceptable potency ranges. [10] That is not unique to Strut Health, but it is a systemic risk for any compounded drug platform.

Peptides: Semaglutide, Tirzepatide, and Beyond

This is the highest-risk category in Strut Health's catalog from a regulatory standpoint. Compounded semaglutide and tirzepatide faced changing FDA status in 2024 and 2025. Beyond the GLP-1 drugs, some telehealth platforms offer peptides such as BPC-157 and CJC-1295, which are not FDA-approved for any indication and are not on the FDA's list of approved bulk drug substances for compounding. The FDA has stated that such peptides cannot be legally compounded under 503A. [11]

Patients who ordered "peptide therapy" through platforms like Strut Health should ask specifically which peptides were dispensed and whether each bulk substance is on the FDA's 503A-approved list. This is not a Strut Health-specific concern; it applies to the entire direct-to-consumer peptide space.

How Strut Health Compares to Other Cash Telehealth Brands

Placing Strut Health in a competitive context helps patients calibrate. The major cash telehealth pharmacy brands in the men's health and peptide space include Hims, Ro (Roman), Done, and Keeps, all of which have generated BBB complaints and regulatory scrutiny at various points.

Complaint Rate Benchmarks

Hims, one of the largest telehealth brands by user volume, had over 200 BBB complaints filed in a 3-year period as of mid-2025, though many were closed as resolved. Ro/Roman has faced state attorney general inquiries in at least two states over subscription billing practices. Strut Health's complaint volume is lower in absolute terms, which is partly a function of smaller market share. On a per-customer basis, the complaint rates across these platforms are broadly similar.

Pricing Transparency

One area where consumer reviews consistently cite Strut Health favorably is pricing transparency. Unlike some competitors that advertise low monthly prices and add fees at checkout, Strut Health displays compound prices before the consultation. Pricing transparency does not compensate for compounding quality concerns, but it does reduce the billing-dispute friction that drives a large share of telehealth complaints industry-wide.

No Insurance = No PBM Audit Layer

All of these platforms operate cash-pay. That eliminates the pharmacy benefit manager (PBM) audit layer that normally flags suspicious dispensing patterns. For patients, this means there is no secondary check on whether the prescription and dispensed product align. The clinician's note is the only documentation trail. Patients should retain their consultation records and prescription details in case of a billing dispute or adverse event.

What Patients Should Do Before Ordering from Strut Health

The following steps are applicable to any cash telehealth pharmacy, and they operationalize the regulatory concepts above into a pre-purchase checklist.

Verify the Dispensing Pharmacy's State License

Ask Strut Health support for the name and DEA number of the dispensing pharmacy. Then look that pharmacy up on your state's board of pharmacy website. Most state boards provide online license-verification tools. If the pharmacy is not licensed in your state, the prescription may not be legal.

Check the FDA Compounding Databases

Visit fda.gov/drugs/human-drug-compounding and search for the pharmacy name. If it is a 503B facility, FDA inspection records are public. If it is a 503A pharmacy, there are no public FDA inspection reports, but warning letters and import alerts are public. [1]

Confirm the Drug's Compounding-Legality Status

For semaglutide and tirzepatide specifically, check whether the drug is still on the FDA shortage list before ordering. The FDA shortage database is updated weekly at accessdata.fda.gov/scripts/drugshortages. [12] Ordering a compounded copy of a drug not on the shortage list after the FDA's compliance deadline may mean receiving an illegally compounded product.

Read the Refund and Cancellation Policy Before Subscribing

The majority of BBB complaints against telehealth pharmacy brands involve auto-renewing subscriptions. Read the cancellation policy before entering a credit card number. If a company requires a phone call to cancel a subscription, that is a friction point worth noting before, not after, subscribing.

Ask for a Certificate of Analysis

For any injectable or high-potency compound, ask the pharmacy for a Certificate of Analysis (CoA) showing potency, sterility, and endotoxin testing results. Legitimate 503A pharmacies can provide this. A refusal to provide a CoA for an injectable compound is a red flag.

A Decision Framework for Evaluating Any Telehealth Compounding Brand

The five questions below form a structured pre-purchase framework applicable to Strut Health or any competitor:

1. Is the dispensing pharmacy licensed in my state? (Check your state board.)
2. Is the active ingredient on the FDA-approved 503A bulk drug substance list? (Check fda.gov.) [1]
3. Is the drug currently on the FDA shortage list? (Required for GLP-1 compounding legality.) [12]
4. Does the pharmacy hold LegitScript certification or equivalent third-party verification?
5. Has the company or its pharmacy received an FDA warning letter in the past 24 months? (Check fda.gov/inspections-compliance-enforcement.) [5]

A "yes" on questions 1 through 4 and a "no" on question 5 does not guarantee safety, but it establishes a regulatory baseline that filters out the most clearly non-compliant vendors.